Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cyclerion Therapeutics
Age
30–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient is ambulatory male or female
Patient's body mass index score is \>20 and \<40 kg/m2 at the Screening Visit
Women of childbearing potential must have a negative pregnancy test at the time of check-in and must agree to use double-barrier contraception throughout the duration of the study
Patient's health is stable with no clinically significant findings on a physical examination
Patient has type 2 (ie adult onset) diabetes mellitus diagnosed by a physician or nurse practitioner \> 6 months before the Screening Visit, and an entry HbA1c that does not mandate prompt intervention for improved control
Patient has hypertension diagnosed by a physician or nurse practitioner \> 6 months before the Screening Visit and BP within the protocol's acceptable range
Patients must be on a stable regimen for glycemic control, and a stable regimen for hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
Patient has abnormal endothelial function measured by the EndoPAT
You may not be if
Patient has a clinically significant active or unstable medical condition that, in the opinion of the Investigator, would preclude trial participation
Patient is on medication(s) that when co-administered with a soluble guanylate cyclase (sGC) stimulator, could increase the risk of hypotension
Patient has evidence of severe or active end-organ damage attributable to diabetes
Patient has severe renal insufficiency, has undergone renal transplantation, or has planned renal transplantation
Clareo Health | A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension
